Lupus nephritis (LN) is an immune infl ammation of kidneys caused by systemic lupus erythematosus (SLE), a chronic infl ammatory disease that aff ects the body' s immune system. Aim of this study was to analyze clinical manifestation and treatment results of patients with LN. Forty one patients with clinical signs of LN were included in the study. Mean age of patients was ,±, years in the moment of fi rst diagnosis of LN, with female-male ratio :. Renal disease was pathohistologically (PTH) verifi ed in , of patients ( pts with class III,  pts with class IV, one pt with class V of lupus nephrites). Patients with high nephrotic proteinuria were treated with pulse dose of methylprednisolone and pulse doses of cyclophosphamide (CYC) in induction therapy. Corticosteroid and CYC were continued according to treatment protocol. e other group of LN patients with lower nephrotic proteinuria was treated with mycophenolate mofetil (MMF) in induction therapy at a dose of x g/day for six months, and than in maintenance x, g/day. e patients with non-nephrotic proteinuria and normal renal function were treated with oral prednisolone ,- mg/kg/day in a single morning dose, and then gradually reduced to the dose of maintenance. e mean time of patient' s follow-up was ,±, years. Partial renal remission was accomplished in , pts, and complete remission in , pts for period of ,±, months from the beginning of the treatment. Duration of complete renal remission was ,±, months. During the period of follow-up, , pts developed at least one nephritic fl are and were treated again. ese results confi rmed that the aggressive form of lupus nephritis should be treated associating cyclophosphamide with corticosteroids therapeutical regiment. MMF is a new promising immunosuppressive drug for a treatment of this serious disease.
Introduction
Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease, which affects kidney in up to  of patients with SLE () . Renal injury is the main cause of mortality and morbidity of patients with SLE () . Lupus nephritis (LN) may be presented from mild asymptomatic proteinuria to rapidly progressive glomerulonephritis with haematuria and red cell casts. Some patients develop acute renal failure, or some degree of chronic kidney disease. Nephrotic syndrome (NS) is present in - of cases. The diagnosis of lupus nephritis is based not only on clinical features alone, than also on renal biopsy, which determines histopathological fi ndings in six classes of lesions.
The treatment of lupus nephritis is focused on reducing disease progression, achievement of complete renal remission and improved long-term outcome of kidney disease. There is general agreement that diffuse or focal proliferative lupus nephritis (class III, IV) is associated with poor renal prognosis and generally requires aggressive therapy. Aim of this study was to analyze clinical manifestations and treatment results of patients with LN.
Materials and Method
Patients with more severe histopathological findings and nephrotic syndrome ( patients) with proteinuria more than  g/day received an induction therapy of methylprednisolone pulse dose of - mg/day for three consecutive days with pulse doses of cyclophosphamide (CyC) of , g per square meter of bodysurface area. Dose of corticosteroid was reduced on ,- mg/kg/day by oral prednisolone for - months and than gradually reduced to the minimum effective dose for maintenance, while pulse doses of CyC were continued according to the treatment protocol. e other group of LN patients ( patients) with nephritic proteinuria between ,- g/day was treated with mycophenolate mofetil (MMF) in induction therapy on a dose of x g/day for  months, and than reduced to the maintenance of x, g/day. All patients (pts) received oral prednisolone ,- mg/kg/day for - months, with gradually tapering to the minimum eff ective dose. The patients with non-nephrotic proteinuria (between , and , g/day) and normal renal function ( pts) were treated with oral prednisolone  mg/ kg/day in a single morning dose - months and then gradually reduced to the dose of maintenance. All the patients were followed up for ,± , years. An induction therapy was started again in any case of fl ares of activity () together with stabilization or normalization of serum creatinine) • relapse of disease (an increase in any renal parameter, as serum creatinine by , so called "nephritic fl are" or proteinuria by ≥ , as "proteinuric fl are"). Treatment failure was defined as a failure to reduce proteinuria by  and/or a sustained increase in serum creatinine by > () . Statistical methods All data are presented as means ± standard deviation (SD). Statistical differences between arithmetic means of numeric variables of each parameter were assessed using Students' t-test. P value < , was considered as statistically signifi cant.
Results
Forty one patients with clinical signs of LN were included in the study. Mean patients age was , ± , years in the moment of fi rst diagnosis of LN ( pts under  years of age). e female-male ratio was : in female favor. e mean lupus disease duration before the initiation of therapy was , ± , years. Renal disease was pathohistologically verifi ed in , of patients ( pts with class III,  pts with class IV, one pt with class V of lupus nephritis). e baseline characteristics of lupus nephritis patients are presented in Table . e thirty () pts received conventional treatment with cyclophosphamide and corticosteroid. In this group LN was clinically presented as: NS in / pts, NS associated with ARI in / pts, only ARI in / pts and CRF with NS in / pts. Out of  patients, who started treatment with MMF (the fi rst one started three years ago),  pts had NS,  pts had NS associated with CRF, while  pt had non -nephritic proteinuria. Four patients with non -nephritic proteinuria treated only with prednisone.
Average values of proteinuria in the beginning of the treatment were signifi cantly higher in the group of patients treated with pulse doses of CyC (p=,), (Table  ) . Signifi cant decrease of proteinuria was accomplished in CYC and MMF groups of patients (p<,), while the last proteinuric values between these two groups were not significantly different (p=,). Average values of serum creatinine between the groups as well as within the groups were not significantly different during the treatment, but the mean serum creatinine was decreased for  during the treatment with CyC (p=,). Recovery of ARI was achieved in / pts.
From CyC group,  pts achieved complete renal remission (/). Nine pts responded to treatment by partial remission, while  pts developed end stage renal disease needing dialysis therapy (they started immunosuppressive therapy in CRF). Duration of complete renal remission was , ± , months. e mean time until achieving complete remission was , ± , months (Table ) .
Five patients from MMF group responded to treatment with complete renal remission, while two developed incomplete remission. Duration of complete remission in this group was , ± , months, which was statistically shorter then in CyC group, but the treatment with MMF was started three years ago, and included a small number of patients.
More complication was notifi ed in CyC group of patients, especially infections. During the treatment with CyC one patient died due to cerebrovascular insults (Table ) . During the period of follow up, , () pts developed at least one nephritis fl are and were treated again.
Discussion
Lupus nephritis is one of the most serious manifestations of systemic lupus erythematosus. Treatment of this disease, especially proliferative forms, requires prolonged aggressive therapy, with aim to reduce disease progression and improve long-term outcome of patient with LN. The choice of the therapeutic strategy may have an important role. It is crucial to define regimes that are effective, but with minimum toxicity, both in the short and long term of follow up. Cyclophosphamide in combination with corticosteroid has improved renal survival compared to steroid alone. "NIH protocol" ( e National Institutes of Health) of intravenous pulsed cyclophosphamide became the standard for treatment of lupus nephritis () . Cyclophosphamide is more potent immunosuppressive agent which leads to a good control of the disease. It has improved the prognosis of LN over the years. Cameron found that life expectancy at  years increased from  in the period - to  in the period - (). In Italian study, which recruited  patients who were followed for a median of  years, renal survival was  at  years and  at  years () . At the last follow-up visit,  patients were in complete renal remission,  were in partial renal remission, four patients had chronic renal insuffi ciency, six had entered end-stage renal disease end six patients had died. In our study mean follow up for all patients was , ± , years. e most common clinical manifestation of LN was nephritic syndrome (,). At the last follow-up visit / pts (,) were in complete renal remission, while , () pts achieved partial renal remission. is happened for period of , ± , months from the beginning of the treatment, a time similar to that observed in other studies using different therapeutical schedules (,) . It was found that many factors infl uence on renal function of patients with LN. They include the diseaserelated complications, over or under treatment and toxic effects of immunosuppressive drugs. The prolonged use of these drugs can be loaded with severe and life-threatening complications. The Euro-Lupus Nephritis Trial examined the effects of "low-dose" ( g ) versus "high-dose" (mean of , g) cyclophosphamide in a randomized study of  patients with lupus nephritis () . Severe infections were more common in the high-dose group, with a trend towards more renal remission in the low-dose group, while the number of renal fl are was no diff erent. We treated patients with LN with protocol of "low-dose" pulse of CyC. Despite that, there were more complications as infections in CyC group compared to MMF group.
Risk of chronic renal failure is higher in patients with increased serum creatinine at the time of the first lupus diagnosis. Some of authors found a prognostic role of anemia (), a high chronicity index at initial renal biopsy () , role of nephritic fl ares () etc. During our study , patients developed at least one nephritic fl are, which required further vigorous treatment.
Mycophenolate mofetil is a relatively new immunosuppressor with selective inhibitory effects on proliferative T and B lymphocytes. A small number of our patients use this drug because it isn't recovered by financial support from official health policy. Our results confi rmed that this drug is also eff ective in significantly reduce of proteinuria and achievement of renal remission with a smaller prevalence of treatmentrelated complications. A meta-analysis of randomized controlled trials by Zhu et al. () defined that MMF in induction therapy signifi cantly increased the complete remission rate and reduced the risk of infection and leucopenia compared with intravenous CyC. Therefore, the high-dose of corticosteroids remains as the mainstay therapy of LN, with adding a second immunosuppressive agent (such as CyC in induction therapy of life-threatening patients with LN, than MMF in maintenance) to reduce iatrogenic morbidity and keep a wished clinical effects with minimal effective dose of drug.
Conclusion
e most patients with LN achieved partial or complete renal remission using diff erent therapeutical schedules. High percentage of treated patients achieved recovery of acute renal failure. We think that aggressive form of lupus nephritis should be treated by associating cyclophosphamide with corticosteroids therapeutical regiment, but the treatment of this disease must be fl exible to the patients and clinical manifestation of disease. MMF is a new promising immunosuppressive drug for a treatment of this serious disease. 
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